Antibody Seronegativity in COVID-19 RT-PCR-Positive Children.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
12
5
2022
medline:
20
7
2022
entrez:
11
5
2022
Statut:
ppublish
Résumé
This substudy of a prospective case-ascertained household transmission study investigated severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction-positive individuals without antibody development and factors associated with nonseroconversion. Approximately 1 of 8 individuals with coronavirus disease 2019 did not seroconvert. Children, particularly the youngest, were approximately half as likely to seroconvert compared with adults. Apart from the absence of fever/chills, individual symptoms did not strongly predict nonseroconversion.
Identifiants
pubmed: 35544731
doi: 10.1097/INF.0000000000003573
pii: 00006454-202208000-00015
pmc: PMC9281420
doi:
Substances chimiques
Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e318-e320Subventions
Organisme : CIHR
ID : VR2-172722
Pays : Canada
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in humans: a systematic review. PLoS One. 2020;15:e0244126.
Yang HS, Costa V, Racine-Brzostek SE, et al. Association of age with SARS-CoV-2 antibody response. JAMA Netw Open. 2021;4:e214302.
Majdoubi A, Michalski C, O’Connell SE, et al. A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2. JCI Insight. 2021;6:146316.
Wei J, Matthews PC, Stoesser N, et al.; COVID-19 Infection Survey team. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nat Commun. 2021;12:6250.
Alshami A, Al Attas R, Anan H, et al. Durability of antibody responses to SARS-CoV-2 infection and its relationship to disease severity assessed using a commercially available assay. Front Microbiol. 2021;12:770727.
Toh ZQ, Anderson J, Mazarakis N, et al. Comparison of seroconversion in children and adults with mild COVID-19. JAMA Netw Open. 2022;5:e221313.
Cholette F, Mesa C, Harris A, et al.; COVID-19 Immunity Task Force (CITF) working group. Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. PLoS One. 2021;16:e0261003.
Colwill K, Galipeau Y, Stuible M, et al. A “Made-in-Canada” serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. medRxiv. 2021. doi: 10.1101/2021.10.25.21265476
doi: 10.1101/2021.10.25.21265476
Smith N, Goncalves P, Charbit B, et al. Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. Nat Immunol. 2021;22:1428–1439.
Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020;323:2427–2429.